Join
Live feed
·
PRReleasevia Quantisnow
Ovid Therapeutics Inc. logo

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

ByQuantisnow·Wall Street's wire, on your screen.
OVID· Ovid Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OVID (Ovid Therapeutics Inc.) and more on Quantisnow.